Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 8/20 | 0.49 |
| ▸ | MMP2 | P08253 | 7/20 | 0.48 |
| ▸ | MMP1 | P03956 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | BMP1 | P13497 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4614445 | 0.91 | MMP2 (0.49) | MMP3MMP2MMP1BMP1 | |
| SCHEMBL4880474 | 0.91 | MMP2 (0.49) | MMP3MMP2MMP1BMP1 | |
| SCHEMBL4888079 | 0.91 | MMP2 (0.49) | MMP3MMP2MMP1KMT2AMEN1 | |
| SCHEMBL4887777 | 0.90 | MMP2 (0.48) | MMP3MMP2MMP1KMT2AMEN1 | |
| SCHEMBL4614374 | 0.90 | MMP2 (0.56) | MMP3MMP2MMP1BMP1 | |
| SCHEMBL4879662 | 0.90 | MMP2 (0.56) | MMP3MMP2MMP1BMP1 | |
| SCHEMBL4887647 | 0.89 | MMP2 (0.48) | MMP3MMP2MMP1BMP1 | |
| SCHEMBL14066493 | 0.88 | MMP2 (0.46) | MMP3MMP2MMP1BMP1 | |
| SCHEMBL4885175 | 0.88 | MMP3 (0.56) | MMP3MMP2MMP1 | |
| SCHEMBL4601109 | 0.86 | KMT2A (0.44) | MMP3MMP2MMP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
| WO-2006115353-A9 | A NOVEL HYDROXAMIC ACID DERIVATIVE AS PEPTIDE DEFORMYLASE INHIBITOR AND MANUFACTURING METHOD THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | PDF, PEPD, DHPS | MMP3 362/4885MMP2 315/4885MMP1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.